What is it about?

The data from the PALLADIUM and IRIDIUM RTC with matched endpoints were pooled to compare treatment options. Breezhaler is a once-daily inhaler of mometasone furoate/indacaterol acetate which can be delivered in a high ( (320/150 µg) or medium-dose (160/150 µg). This treatment course was compared to twice-daily fluticasone propionate/salmeterol xinafoate over a 52 week study period.

Featured Image

Why is it important?

The analysis showed that high-dose MF/IND one time a day reduced the rate of severe exacerbations by 26%, moderate or severe exacerbations by 22%, and the rate of all exacerbations by 19% compared with high-dose FLU/SAL two times a day. Along with improvements in morning and evening PEF and rough FEV1, with comparable safety to FLU/SAL twice daily.


With 30-50% of asthma not well managed while following the standard treatment of inhaled corticosteroid (ICS)/long-acting β2-agonist therapies, patient alternatives are needed. Mometasone furoate/indacaterol acetate in Breezhaler® as a once-daily ICS can be a viable alternative for many with poor asthma control. The once-daily administration could also offer benefits in adherence compared to a twice-daily plan.

Professor Kenneth R Chapman
University of Toronto

Read the Original

This page is a summary of: One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies, BMJ Open Respiratory Research, August 2021, BMJ,
DOI: 10.1136/bmjresp-2020-000819.
You can read the full text:



The following have contributed to this page